Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $9.00

Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last […]

Leave a Reply

Your email address will not be published.

Previous post StockNews.com Downgrades Golub Capital BDC (NASDAQ:GBDC) to Sell
Next post Manhattan Associates, Inc. (NASDAQ:MANH) Receives $257.43 Consensus Target Price from Brokerages